Drug intelligence / Profile preview

abp 234

Development stage: Phase 3
Lead developer: Amgen
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

ABP 234 is an investigational biosimilar to pembrolizumab (marketed as Keytruda), developed by Amgen. It is a monoclonal antibody that binds to the programmed cell death protein 1 (PD-1) receptor on T cells, blocking its interaction with PD-L1 and PD-L2 ligands. This antagonism releases the inhibition of T-cell activity, thereby enhancing anti-tumor immune responses. ABP 234 is being evaluated primarily for the treatment of non-small cell lung cancer in phase III clinical trials[1][3][4][7]. As a biosimilar, it aims to match the efficacy and safety profile of reference pembrolizumab.

Other names: pembrolizumab biosimilar

Targets

PDCD1 (Programmed cell death protein 1 receptor)

Beyond the preview

Go deeper on abp 234.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on abp 234.

Explore the full profile